http://www.alliedminds.com/

"Allied Minds is an innovation company that forms, funds, manages and builds startups based on early-stage technology originating from U.S. universities and federally funded research institutions. We created a new business model for overcoming early-stage development gap between basic research and commercial development. Our investors are aligned with our vision that cutting-edge invention is an attractive, yet under-developed, asset class. We review numerous ideas but only select opportunities with potential to deliver outsized returns. We create subsidiaries led by seasoned management who know how to turn academic breakthroughs into commercial products and then take them to market. We provide our subsidiaries with capital resources, from seed to self-sustainment. Our aim is to promote growth, generate jobs, foster innovation and create societal benefit."

StockMarketWire.com
Allied Minds has confirmed that its entire issued ordinary share capital of 209,499,425 ordinary shares has started trading on the London Stock Exchange's main market under the ticker 'ALM', 25th June 2014. Flotation price 190p.

(BOSTON and NEW YORK - Aug 4, 2014)
- Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY) today announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S.
Allied-Bristol Life Sciences LLC will focus on efficiently and effectively converting discoveries from university research institutions into therapeutic candidates for clinical development, and ultimately approved therapies that address serious diseases. For programs identified by the new enterprise, university researchers will be able to access Bristol-Myers Squibb's drug discovery research expertise, and Allied Minds' financial and management experience.
"The innovations developed in U.S. research institutions represent an important resource for scientific advancement, as well as economic development and financial returns," said Chris Silva, Chief Executive Officer of Allied Minds. "Our partnership with Bristol-Myers Squibb combines complementary strengths, resources, reach and expertise to create an exciting new paradigm in the drug development space."
Allied-Bristol Life Sciences LLC brings together cutting-edge ideas, BioPharma experience and drug discovery expertise focused on maximizing the potential of new scientific approaches to addressing serious disease," said Carl Decicco, senior vice president and Head of Discovery, Bristol-Myers Squibb. "We believe this new venture will enhance the translation of early-stage academic research and will ultimately help advance important potential new medicines more efficiently."

Allied Minds Announces the Formation of Whitewood Encryption Systems, Inc.

· Whitewood aims to develop next-generation systems of data encryption that leverage advanced cryptography technologies originating from U.S. research centers.
· Whitewood was founded upon technologies created at Los Alamos National Laboratory, and its initial products are expected to include a quantum random number generator and a system of quantum key management.


Boston (August 27, 2014) - Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company, announced today the formation of Whitewood Encryption Systems, Inc., a builder of next-generation systems of data encryption that leverage advanced cryptography technologies emerging from U.S. centers of research excellence. Additionally, the company announced today it has exclusively licensed intellectual property from Los Alamos National Laboratory for quantum cryptography.

Whitewood seeks to meet the growing demand for cryptography products that can protect consumers and businesses from a rapidly escalating number of malicious, costly - and increasingly sophisticated - security attacks and data leakages. Whitewood's advanced cryptography systems will provide defenders with enhanced security through scalable, cost-effective solutions that meet high-speed requirements for the efficient transfer of data.

The company's initial products, anticipated to be a high-entropy, high-throughput quantum random number generator and a next-generation, scalable system of quantum key management, will be founded upon technologies created at Los Alamos National Laboratory. These technologies, backed by nearly two decades of research, are expected to offer unprecedented levels of speed and security for data encryption by providing a quantum physics-based alternative to traditional cryptographic practices.

Allied Minds Announces Half-Yearly Results

http://www.moneyam.com/action/news/showArticle?id=4875343

HY14 Financial Highlights

· Net cash and cash equivalents at 30 June 2014: $228.5m (FY13:$104.6m)

· Revenue: $2.9m (HY13: $0.7m)

· Net loss: $27.2m (HY13: $17.6m), of which $21.9m attributable to Allied Minds (HY13: $13.6m)

"The successful completion of the IPO marks the beginning of an exciting new phase of growth and opportunity for Allied Minds and our diversified portfolio of 20 businesses. We are pleased with the positive response that we received from investors to the IPO, and look forward to enhancing and accelerating our efforts to commercialise the innovative science and technologies from our extensive network of partners at U.S. universities and government research institutions."

One of the few IPO's which has done well since float recently. Up another 6% today.

Not far from the £3 mark. I think 320p was the last broker target I saw.

Nice find Harry - I wish I'd found the thread in July!

Last/only broker :- 08 Aug 14 Jefferies International Buy 298.50 - 320.00 Initiates/Starts

StockMarketWire.com
Allied Minds, an innovative US science and technology development and commercialisation company, has announced the launch of Novare Pharmaceuticals.

Novare is a biotechnology company focused on developing therapeutic products that help the body replenish and rebuild itself using its own tissue through the modulation of RHAMM. Modulation of RHAMM is also of benefit in inflammatory diseases such as Bronchopulmonary Dysplasia (BPD).

Novare is an expansion of the Allied Minds subsidiary previously called ProGDerm, which is developing a dermal filler for aesthetic applications that works via the modulation of the Receptor for Hyaluronan Mediated Motility, or RHAMM.

This research is being led by Dr. Eva Turley, an oncology scientist at the London Health Sciences Centre (LHSC) in London, Ontario, in collaboration with MJ Bissell, a world-renowned cell biologist at Lawrence Berkeley National Laboratories in Berkeley, California.

Turley and colleagues have now uncovered the potential for additional applications of RHAMM modulation that may help solve some of today's biggest medical challenges, including arthritis, fibrotic diseases such as Bronchopulmonary Dysplasia (BPD) in premature infants and Idiopathic Pulmonary Fibrosis (IPF), and the reduction and possible elimination of keloid scars.

This breakthrough in tissue engineering may also provide an opportunity to regenerate and reconstruct women's breasts after a mastectomy through the localized stimulation of the body's own adipocyte (fat) stem cells. Novare has licensed from LHSC additional RHAMM compounds discovered by Dr. Turley, who is also serving as Novare's Chief Scientist, and Dr. Leonard Luyt, a peptide chemist at LHSC, allowing the company to more than double its library of RHAMM-binding peptides - and increase potential applications. Novare chief executive Michael Delmage said: "We are excited by the opportunity to further explore the potential therapeutic applications of RHAMM modulation technologies as the studies conducted to date show promising, medically relevant, drug-induced biological responses."

StockMarketWire.com
Allied Minds subsidiary Spin Transfer Technologies has raised $70m to accelerate commercialisation of its innovative computer memory technology. STT's patented OST-MRAM technology is a disruptive innovation in the field of spin-transfer-based MRAM devices by enabling faster switching speeds, lower power operation, reduced manufactured device cost and scalability to smaller lithographic dimensions.

OST-MRAM's application areas can potentially address large parts of the semiconductor market - in particular, the standalone memory markets and the embedded memory market in logic, microprocessors/microcontrollers and analog integrated circuits.

Woodford Investment Management (WIM) led this round of financing, demonstrating its continued support for the commercialization model of academic research pioneered in the U.S. by Allied Minds. In addition, Invesco Asset Management (Invesco) increased its stake and maintains its position as the largest institutional investor in the Fremont, California-based company. SandAire, a private wealth investment fund in London, joined the investor group with its participation in the financing.

StockMarketWire.com
Allied Minds is entering into an exclusive, worldwide licensing agreement with Columbia University that has led to the formation of a new subsidiary, Seamless Devices, Inc.

Seamless Devices is developing applications for a novel technique in analog signal processing that will make it possible to produce high-performance signals even as transistors are scaled down in size deep into the nanoscale.

The technology, developed in the laboratory of Columbia University Electrical Engineering Professor Peter Kinget, serves a wide range of applications across several industries, including consumer electronics, telecommunications hardware, instrumentation, network hardware, healthcare devices, transportation and military systems.

Appointment of Joint Broker
Allied Minds plc (LSE: ALM), an innovative U.S. science and technology development and commercialisation company, is pleased to announce that it has appointed Numis Securities Limited as joint Corporate Broker to the Company, alongside Jefferies Hoare Govett, with immediate effect.

SciFluor Life Sciences Awarded U.S. Patent for Integrin αvβ3 Inhibitors Designed for the Topical Treatment of Retinal Disease
· Patent-protected topical integrin antagonist could potentially revolutionize retinal disease therapy.

· Addressable markets include wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).

· Issuance of first patent validates SciFluor's innovative approach to small molecule drug discovery by the strategic incorporation of fluorine.


Cambridge, Mass. (Dec. 4, 2014) - SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,901,144 with claims covering the novel compound SF0166. SciFluor's SF0166 is a small molecule integrin antagonist designed to treat retinal disease, including Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), via topical administration to the eye.

Topical administration of medications (eye drops) for treating the retina in order to eliminate the need to inject compounds to the back of the eye has been considered an enormous challenge until now. Current treatments require repeated injections into the back of the eye in order to get enough of the drug where it is needed. A drug that could localize in the back of the eye after administration as an eye drop would remove the need for repeated injections. To date, no topically administered drug has been approved for these indications.

Ben Askew, PhD, Vice President of Research, said, "The issuance of the patent covering SF0166 provides validation of our fluorine-centered approach to rapidly bringing new transformational therapies to patients with serious illnesses. SF0166 demonstrates how the appropriate fluorine-containing modifications can improve the physical properties of a molecule to address the challenge of getting enough drug to the back of the eye without injections."

Dr. Askew is the lead on the SF0166 therapeutic program, which is targeted to treat both wet Age-related Macular Degeneration (AMD) as well as Diabetic Macular Edema (DME).

"The scientific depth of this team and the team's ability to rapidly evolve this candidate and to obtain an issued patent protecting this lead compound in such an enormous field of retinal disease is highly impressive. We are excited to advance this program. This is the first of many opportunities at SciFluor that we are pursuing to strategically capitalize on the transformational power of fluorine," said Omar Amirana, MD, SciFluor's Chief Executive Officer and Senior Vice President at Allied Minds.

SciFluor is a subsidiary of Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company.

330p. Pushing into new territory!

StockMarketWire.com
Allied Minds subsidiary SciFluor Life Sciences has been awarded a US patent covering the novel compound SF0034, a potent and selective neuronal potassium channel activator, designed to be a significantly improved version of the first-in-class KCNQ2/3 activator drug, ezogabine (POTIGA).

POTIGA was approved in 2011 for treatment of partial-onset epilepsy in adults, but its clinical use was severely restricted in 2013 due to latent toxicities which are not thought to be associated with its mechanism of action.

Numis note today:
"US universities and federal research laboratories spend over $170bn pa on research, and Allied Minds has built a network of over 60 such organisations from which it identifies novel IP and technologies. It forms companies around this IP, providing funding, management and legal and back office support for c.80-100% of the equity. Allied Minds has formed 21 subsidiaries to-date, with its holdings valued around $411m and with another c.$175m cash able to be deployed. The company has almost $250m of capital to invest in its existing portfolio and to develop new companies, so we believe that it is well capitalised to continue to build value. We value Allied Minds at 455p/share, implying 2.5x based on an assumption of 10-year IRR of 26% (compared to c.60% historical IRR), and initiate research coverage with a Buy rating.
The largest two holdings are:
Spin Transfer Technologies (STT) has developed a next-generation memory technology, which potentially has speed, reliability, energy consumption and cost benefits over incumbent technologies – we estimate that the addressable market is over $70bn. The company has already made significant technical progress and has recently been funded for the next phase of development, which should result in prototype products shipping in late CY15. It is most likely that an IP business model will be used, where STT licenses the technology to existing players in the memory market and earns royalties on chip sales (similar to ARM). However, the company may be acquired by one of those players if momentum around its technology continues to build.
RF Biocidics (RFB). With one in six people per year suffering from food-borne illnesses, and increasing regulatory emphasis on prevention, we believe that food disinfection will remain a growing trend. Existing disinfection methods have significant drawbacks, so RF Biocidics has developed a new system that uses radiofrequency. This has been integrated into two products that have already been sold to some major food producers.
Forecasts. Allied Minds' control over its subsidiaries means it consolidates their accounts, thus showing investment as operating and investing cash outflows. We model STT and RFB together generating $60m of revenue by 2018, which helps to offset an investment rate we model at $50-60m pa. Key risks include unanticipated technical hurdles at STT and slower commercial adoption of RFB's products.

Now more than doubled since the float. Currently 435p mid .

Has now passed the Numis price target of 455p. Possibly getting a little ahead of itself now? Consolidation (pause for breath) would make me happy now!

Looks like you have been on your own here HARRY , good pick .

Thanks jimmy. Going like a train! Trouble is, I have no idea why! No news, yet sp now surged past the £6 level.

Yes - fancy keeping these to yourself Harry! :-)

5th Sept was your last look skinny and you passed! On my part this is luck more than judgement! It's going up relentlessly but I don't really know why!!! Even the last broker note is not particularly enlightening on how it has valued the stock.

Well he posted 18 times over the last 6 months and we ignored him !!

Possibly now due to this:
"26-Feb-2015
Optio Labs Names Former Samsung Executive Bryan Glancey as Chief Technology Officer."

Though even ALM are cautious about their strategy!
"Allied Minds Forward-Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the company’s regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise."

Harry - I can only echo what I posted then - well done!

Brokers still some way behind the curve - as per normal.

Too far, too fast. Nice and steady preferred!

Boston (March 10, 2015) - Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company, announced the formation of BridgeSat, Inc., which is building an optical connectivity system to improve the wireless transfer of data from satellites.

BridgeSat co-invented the technology with The Aerospace Corporation as part of a commercialization collaboration for the portfolio of innovations created at the federally funded research and development center (FFRDC). Aerospace has a long history of developing technologies for space, including 15 years of experience building small satellite technologies for both commercial and government entities.

"The Aerospace Corporation is a key player and leader in all aspects of space communication systems and technologies," said Dr. Sherrie Zacharius, Vice President of Technology and Laboratory Operations. "Through our robust research and development endeavors, we have established a rich portfolio of innovative building-block technologies applicable to broad public needs. This collaboration with Allied Minds, which led to the formation of BridgeSat, provides an avenue for technology transfer to the commercial sector for the common good."

"Our research with The Aerospace Corporation has allowed us to explore new, more effective options for LEO data transmissions," said John Serafini, Vice President at Allied Minds. "At BridgeSat, we believe we've solved challenges including size, weight, cost and power bottlenecks that had traditionally hampered optical-based data downlink, as the technology ultimately offers substantial benefits over traditional RF downlink."

Demand for accurate and frequent data collection from LEO satellites is expected to accelerate aggressively over the next decade amidst declining costs for building and launching satellites. BridgeSat has partnered with Draper Laboratory to develop the system that will provide an alternative downlink mechanism that is faster, more secure, and available at a lower cost to traditional radio-frequency transmissions.

"Draper's expertise in space systems technologies, optics and secure digital data links, as well as its experience in applying its capabilities to expanding commercial markets, will help BridgeSat mature its concepts throughout development and operations," said Dr. Seamus Tuohy, director of Space Systems at Draper Laboratory.

BridgeSat has also engaged with Dr. Kerri L. Cahoy, Assistant Professor of Aeronautics and Astronautics at the Massachusetts Institute of Technology (MIT). Dr. Cahoy will serve as a Senior Advisor to the company. BridgeSat has optioned a relevant selection of intellectual property from Cambridge, Massachusetts-based MIT.

"Optical communications offer a significant advantage in both resource utilization and security. We are innovating to improve and miniaturize spacecraft-pointing capabilities, an important enabler for higher-rate narrow beam optical systems, improved transmitter efficiency and the development of low-cost, easily deployed, and effective ground systems," said Dr. Cahoy.

BridgeSat, Inc. is a subsidiary of Boston-based Allied Minds. More information about the company and its research can be found www.BridgeSatInc.com.

StockMarketWire.com
Allied Minds, an innovative US science and technology development and commercialisation company, will announce its full year 2014 results at 7 a.m. on 28 April.

Allied Minds will also host a capital markets day event on the same day, to be held at Etc. Venues St Paul's, 200 Aldersgate Street, EC1A 4HD.

Allied Minds' Subsidiary SciFluor Life Sciences Raises $30 Million and Names William Koster, PhD, Former CEO of Neurogen Corp., as Chairman
· SciFluor's recent advancements in its pipeline, comprised of two lead compounds and additional discovery assets using the strategic incorporation of fluorine to create best-in-class drugs, generated investor interest.
· SciFluor's plans to develop fluorine-containing new chemical entities (NCEs) across multiple disease states will benefit from the addition of William Koster, whose accomplishments include success in senior executive roles in small molecule drug discovery and early clinical development at Neurogen Corp. and Bristol-Myers Squibb Co.

Appointment of New Non-Executive Chairman
Allied Minds plc, an innovative U.S.-focused science and technology development and commercialisation company, today announces that Mr. Peter Dolan will be appointed to the role of Non-Executive Chairman of the board of directors of the Company ("Board"), with effect from the conclusion of the Company's Annual General Meeting on 28 May 2015. Mr. Dolan will replace the current Executive Chairman, Mr. Mark Pritchard, who will remain on the Board in an executive capacity in the short term but intends to step down from the Board later in the year, although he is expected to continue to be actively engaged with the Company. Mr. Pritchard founded Allied Minds in 2004 and has been directly involved in its strategic direction and growth since inception, most recently taking the role of Chairman of the Board as the Company listed on the Main Market of the London Stock Exchange in June 2014. The appointment of Mr. Dolan, an independent non-executive director, will further the Company's compliance with best practices of the UK Corporate Governance Code.

Placing of Shares in Allied Minds plc
20 May 2015

Further to the announcement released on 19 May 2015, Invesco Asset Management Limited, in its capacity as agent for and on behalf of its discretionary managed clients ("Invesco") has sold 16 million ordinary shares of Allied Minds (the "Placing Shares") at a price of 565 pence per share, raising gross sale proceeds of £90.4 million.

The sale on behalf of Invesco was completed via an accelerated bookbuild to institutional investors conducted by Jefferies International Limited ("Jefferies") and Numis Securities Limited ("Numis") as joint bookrunners (the "Placing"). Allied Minds will not receive any proceeds from the Placing.

Following settlement of the Placing, Invesco's discretionary managed clients are expected to hold approximately 34.5 per cent. of the Company's issued share capital.

The proceeds of the Placing are payable in cash on usual settlement terms, and closing of the Placing is expected to occur on a T+2 basis on 22 May 2015, subject to the satisfaction or waiver of certain customary conditions.

Invesco has indicated that, following completion of the Placing, it intends to remain a significant, long term shareholder of the Company.

Annual General Meeting
Allied Minds plc, an innovative U.S.-focused science and technology development and commercialisation company, is holding its Annual General Meeting (AGM) today. No new information on current trading will be given during the meeting.

The Company will release its 2015 Half Yearly Report on 27th August 2015.

StockMarketWire.com
Allied-Bristol Life Sciences - a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb Company - has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Whitman's lab at the Harvard School of Dental Medicine.

Malcolm Whitman, PhD, Professor of Developmental Biology, and Tracy Keller, PhD, an instructor in the Department of Developmental Biology, have identified the mechanism of action behind a known natural product, halofuginone (HF).

HF is a chemical compound based on an active ingredient in the root of the blue evergreen hydrangea (Dichroa febrifuga), which has been used in traditional Chinese medicine for centuries.

Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Children's Hospital, Professor Whitman's lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction (AAR) response pathway.

Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases.

StockMarketWire.com
Allied Minds posts a loss of $39.1m for the six months to the end of June compared with $27.2m a year ago.

Revenue fell to $1.5m (HY14: $2.9m) which was primarily attributable to the lower product revenue at RF Biocidics, offset by the grant revenue at SiEnergy from the ARPA-E award.

Revenues at CryoXtract and SoundCure remained relatively consistent when compared to the same period in the prior year.

Cost of revenue was lower by $1.2 million, at $0.7 million for the six months ended 30 June 2015 (HY14: $1.9m) as a result of the lower sales in the period, when compared to the same period in the prior year.

The company also announced that its joint venture with Bristol-Myers Squibb Co, Allied-Bristol Life Sciences, has licensed a proprietary platform technology from Yale University, developed in the laboratory of Dr. David Spiegel.

The proprietary platform, and associated lead molecules known as Antibody-Recruiting molecules (ARMs), provide a novel approach for the treatment of cancer.

Allied Minds Announces the Formation of HawkEye 360
● The company will use small satellites in low Earth orbit (LEO) to collect data, perform analytics and generate reports on wireless signals worldwide that can be used to monitor and track ships, planes and other transportation networks across air, land and sea, and assist with emergency response.

● The three founders of HawkEye 360 bring valuable experience: Mr. Chris DeMay previously worked for the U.S. National Reconnaissance Office, leading programs for satellite development. Dr. Charles Clancy and Dr. Bob McGwier of Virginia Tech's Hume Center for National Security and Technology developed the associated technology for the complex RF signal processing.

http://www.moneyam.com/action/news/showArticle?id=5114795

This is a very detailed report from a hedge fund on why NOT to invest in ALM:

http://kerrisdalecap.com/wp-content/uploads/2015/09/Allied-Minds-Report.pdf

StockMarketWire.com
Allied Minds subsidiary Precision Biopsy has raised $33.6m in new equity investments as the company embarks on a global commercialisation strategy for its ClariCore Biopsy System, a device platform designed to provide accurate, real-time classification of prostate tissue during biopsy procedures. Precision Biopsy also plans to accelerate the development of its Focal Therapy program, which seeks to provide targeted, localised therapy to the prostate gland by using the same optical tissue-targeting technology found in the ClariCore system.

Woodford Investment Management led this round of financing, which included Allied Minds, and demonstrates the continued support for the business and these growth initiatives.

StockMarketWire.com
Allied Minds subsidiary, Spin Transfer Technologies, has successfully demonstrated its Spin Transfer Magneto-Resistive Random Access Memory technology through the production of a working prototype device.

This milestone achievement also proved the company's advanced prototyping magnetics processing line at its facility in Fremont, California, is now fully operational.

The prototypes incorporate proprietary, performance-enhancing 'spin-filtering' technology, and were fabricated on industry standard CMOS wafers sourced from a high volume Asian foundry supplier. STT was able to demonstrate ST-MRAM that delivers fully operational integrated memory functionality.

StockMarketWire.com
Allied Minds saw positive progress in 2015 with its subsidiaries meeting or exceeding commercial milestones in nearly all instances.

Chief executive Chris Silva said: "We have embarked on exciting collaborations with industry leaders such as Bristol-Myers Squibb, Intel, AMD and Google; raised material third-party funding to accelerate the development of two of our key subsidiaries; and seen the number of commercialisation phase subsidiaries double to six.

"Our US academic and federal partner network is continuing to flourish and has been highly productive over the year. We reviewed more than 5,000 new technologies and engaged with over 90 new research institutions, reflecting the growing recognition of the strengths of Allied Minds as a commercialisation partner. We continue to apply our rigorous selection and due diligence processes to these new technologies and are confident in the potential of our pipeline.

"The range and depth of our achievements during 2015 has laid strong foundations for Allied Minds to continue to generate further value in 2016 and beyond."

all good news, but losses, are potent, rev down, cash to last don't know, no
directors buying receintly none. BB. s/p 440p ps. holder reduces.

StockMarketWire.com
Allied-Bristol Life Sciences - a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb Co - has launched a new subsidiary, iβeCa Therapeutics, to license proprietary compounds from NYU School of Medicine that target the Wnt signalling pathway.

The Wnt pathway plays a key role in the development and progression of a number of cancers affecting large numbers of patients.

iβeCa Therapeutics will focus on further discovery and development activities needed to identify candidates for human clinical testing.

StockMarketWire.com
Allied Minds, through its newly formed subsidiary, ABLS Capital, it has secured investment commitments of $80 million to fund up to 10 potential lead optimisation programmes of promising drug development opportunities that have successfully completed an initial candidate feasibility programme.

Under the terms of the ABLS partnership formed between Allied Minds and BMS in 2014, BMS is committed to fund an additional $20 million along with these commitments.

Investors in ABLS Capital include Woodford Investment Management (committing to fund up to $40 million), Invesco Asset Management (committing to fund up to $20 million), as well as Allied Minds and others.

ABLS is a drug discovery company focused on identifying and developing biopharmaceutical innovations from leading U.S. universities and research institutions that it believes have significant therapeutic and commercial potential. ABLS focuses on early-stage opportunities in key therapeutic areas, including fibrosis, cardiovascular, oncology, immunology and genetically defined diseases. ABLS forms and funds new subsidiary companies to conduct an initial feasibility programme on identified discoveries. Upon completion of a successful feasibility program, ABLS arranges for additional funds to be provided to such ABLS subsidiary for the next stage of development. ABLS Capital will provide 80% of the funds for this critical next stage, and together with the 20% of funds provided by BMS, will ensure that up to ten ABLS subsidiaries will have the necessary capital to seek to identify pre-clinical drug candidates. Chris Silva, CEO of Allied Minds, said: "This is another exciting step forward for achieving the goals of ABLS, which was formed less than two years ago. Backed by supportive new investors and together with our partner Bristol-Myers Squibb, we have secured sufficient funding commitments for the pre-clinical development of up to ten drug candidates. Each of these have the potential to address areas of great unmet medical need across very sizeable markets."

FOR RELEASE ON 13 MAY 2016

Allied Minds plc (the "Company" or the "Group")

Director / PDMR Shareholding

Allied Minds plc (LSE: ALM), an innovative U.S.-focused science and technology development and commercialisation company, announces that it received notification from Marc Eichenberger, Chief Operating Officer, a person discharging managerial responsibility ("PDMR"), regarding the sale of the Company's ordinary shares of one pence each ("Ordinary Shares").

The Company was notified that, on 09 May 2016, Mr. Eichenberger sold 37,980 Ordinary Shares at a price of 344.6083 pence per share, and on 10 May 2016, Mr. Eichenberger sold 11,262 Ordinary Shares at a price of 335.4364 pence per share.

Interesting stock will do some research.

Be careful mitzy. This is really a venture capital company, which is attempting to invest in high risk, but hopefully very profitable research. I have owned the stock from the outset, but took profit when the sp was up in the 700p level. I agree it is dabbling in very interesting areas, but with the associated risks attached!

Thanks Harry I realise its a high risk stock and it has fallen again today will watch it for the time being.

StockMarketWire.com
Allied Minds has secured a $20 million, one-year revolving debt facility from Silicon Valley Bank.

The facility is secured over certain assets of the group. To secure the facility, the group was required to meet certain financial strength tests set by SVB.

Chief executive Chris Silva said: "We are pleased to have SVB's support as we continue to build and develop our portfolio and look forward to what we anticipate will be a long-term relationship with SVB. The SVB facility further diversifies our capital structure and is a powerful endorsement of the Group's growth and development prospects."

Separately, the group also said its subsidiary, ABLS II, had raised $15 million.

On 25 May, Allied-Bristol Life Sciences, LLC announced that it had successfully completed the drug candidate feasibility programme at ABLS II, LLC (ABLS II) for novel small molecule therapeutics for the treatment of fibrotic and autoimmune diseases

ABLS II has now raised $15 million of new equity in a Series A Preferred round from investors including ABLS Capital, LLC ($12 million) and Bristol-Myers Squibb Company ($3 million) to fund further development of the lead optimisation programme

To fund its portion of the ABLS II financing, ABLS Capital has raised $12 million of new equity in a Class B shares round from investors including Woodford Investment Management ($6 million), Invesco Asset Management ($3 million) and Allied Minds

Allied Minds' economic interest in ABLS II is 35.95%, arising from its 80% interest in ABLS and 30.25% interest in ABLS Capital

Should this next lead optimisation phase prove successful, Bristol-Myers Squibb has the right to acquire Allied Minds' interest in ABLS II at a pre-determined multiple of invested capital.

StockMarketWire.com
Allied Minds posts a pre-tax loss of $52.2m for the six months to the end of June - up froma a restated $39.8m last time. Revenues totalled $1.3 - down from $1.5m a year ago.

Operating losses rose to $51.3m from $39.6m.

Chief executive Chris Silva said, "We continue to deliver on our strategy and our commitments to shareholders. Significant capital was invested into new and existing subsidiary businesses during the reporting period, with an increasing proportion of this funding now being derived from third party investors. This is testimony that the commercial value of our most promising subsidiary companies is now being recognised within the sectors they operate, a trend which is also helping us build yet further partnerships with world class corporations. We continue to add to our portfolio and several of our most promising companies are making strong strides towards commercialisation. This progress gives the Board every confidence for the future of the Group."

StockMarketWire.com
Allied Minds' subsidiary Precision Biopsy has raised an additional $5.0 million in new equity from the sale of additional Series A Preferred shares to investor Woodford Investment Management, as the company continues its global commercialization strategy for its ClariCore Biopsy System, a device platform designed to provide accurate, real-time classification of prostate tissue during biopsy procedures.

The funds will also be used to continue the development of the company's Focal Therapy programme, which seeks to provide targeted, localised therapy to the prostate gland by using the same optical tissue-targeting technology found in the ClariCore system.

"We are delighted to receive the additional support from our leading institutional investor as we prepare to bring our ClariCore Biopsy System to market," said Amir Tehrani, chief executive officer of Precision Biopsy. "We believe that the ClariCore system will help to improve the diagnostic process for millions of patients who undergo biopsy procedures each year to monitor for prostate cancer, the second-most deadly cancer in men after lung cancer."

StockMarketWire.com
Allied Minds has announced the formation of a new subsidiary, Vatic Materials, which has entered into an exclusive option to license certain proprietary technology from The Pennsylvania State University (Penn State).

Vatic Materials plans to focus on developing materials and fabrication processes for advanced transparent conducting thin films that will enable conductive surfaces that are potentially thinner and more cost effective than current approaches.

Transparent conducting thin films are ubiquitous in modern electronics, enabling high performance touchscreens, lighting, photovoltaics, and more.

The proprietary technology, developed in the laboratory of Penn State Materials Science Professor Roman Engel-Herbert, could be used to serve a wide range of applications across several industries, including consumer electronics, photovoltaics, advanced building materials, and solid-state lighting.

StockMarketWire.com
Allied Minds subsidiary HawkEye 360, a developer of a space-based radio frequency (RF) mapping and analytics system, has raised $11.0 million in new equity investments in a Series A preferred financing led by Razor's Edge Ventures, with additional participation by Allied Minds and a defence market leader.

HawkEye 360 also intends to issue up to an additional $2.75 million in Series A preferred shares to new and existing shareholders within 60 days, resulting in a total expected financing of up to $13.75 million.

The funds will be used to complete the development and manufacturing of the HawkEye 360 Pathfinder Cluster of three small satellites, which is scheduled for launch and testing in late 2017, as well as grow the company's engineering and business development teams.

Allied Minds PLC (LON:ALM) was downgraded by research analysts at Jefferies Group LLC to an “underperform” rating in a research report issued to clients and investors on Friday. They currently have a GBX 254 ($3.19) price target on the stock, down from their prior price target of GBX 584 ($7.34). Jefferies Group LLC’s target price suggests a potential downside of 21.02% from the stock’s current price.

StockMarketWire.com
Allied Minds has announced a restructuring and the reallocation of capital and management resources across the portfolio and pipeline which would result in discontinued funding for seven subsidiaries.

The group said a process would be undertaken to seek strategic alternatives for these businesses, which could include sales or transfers of legal entities or assets, or liquidations.

Capital and management resources unlocked from this process would be diverted to other companies and opportunities in the portfolio where there was greatest potential for value creation.

It aid attention would be focused in particular on its more advanced subsidiaries and most promising early stage companies, and on scaling its origination platform to take full advantage of opportunities across its network of research institutions and corporate partnerships.

It said the seven discontinued subsidiaries were: Biotectix; Cephalogics; CryoXtract; Novare Pharmaceuticals; Optio Labs; RF Biocidics; and Tinnitus Treatment Solutions.

It said discontinuation of funding at these subsidiaries would free up approximately $14m of capital spend budgeted for 2017 but so far not undertaken, or approximately $9m net of a restructuring charge currently estimated at $4.7m to be taken in the second quarter.

As at 30 June 2016 the discontinued subsidiaries in aggregate represented $146.6 million of Allied Minds' group subsidiary ownership adjusted value (GSOAV).

The group said it was currently expected that this value would be marked down in its entirety on publication of the full year results, but with some modestly offsetting net positive movements elsewhere in the portfolio.

Allied Minds is a failing company lacking innovation and also funding. Sell. Now 204p

This has gone way below its IPO price in 2014. Now 168p as Invesco has reduced its stake in Allied Minds.

Numis today reaffirms its hold investment rating on Allied Minds PLC (LON:ALM) and set its price target at 165p.

Jefferies International today (03/05/17) reaffirms its hold investment rating on Allied Minds PLC (LON:ALM) and cut its price target to 176p (from 195p).

StockMarketWire.com
Allied Minds portfolio company BridgeSat has completed a $6m series A funding round, including participation from Space Angels, an early stage investment group comprising experts in the Space 2.0 field.

Allied Minds said the fundraise was completed at a pre-money valuation of $15m, up from the previous valuation of $7m.

It said proceeds would be used to accelerate the three core elements of BridgeSat's solution: space terminal (the equipment fixed to customer satellites), ground stations (receiving the data from space) and network (transmitting the data to end customers via cloud based software).

Allied Minds chief executive Jill Smith said: "We are excited by the rapid progress BridgeSat has made in advancing the key elements of its optical downlink network; a technology that has the potential to unlock significant benefits for the large and fast growing LEO data downlink market.

"The participation of Space Angels in this funding round is an important validation for the business, and is consistent with our objective to broaden Allied Minds' funding syndicate and secure investment from strategic and independent financial investors at an earlier stage in our subsidiaries' development.

"The BridgeSat fundraise follows the successful Series A round for HawkEye 360 completed at the end of 2016, and underlines Allied Minds' growing expertise in the satellite and data management verticals."

StockMarketWire.com
Allied Minds portfolio company Signature Medical has completed a $2.5 million series A preferred financing round, including participation by Riot Ventures, an early stage investment fund focused on emerging technology, and Bose Corporation, a global leader in audio innovation.

Signature Medical is developing wearable devices using acoustic signature analysis and artificial intelligence allied to cloud-based technology to evaluate and monitor patients remotely and on a real time basis.

Its lead AcoustiCare device is designed for patients with heart failure and other indications.

Proceeds from the financing will be used to fund product development.

Allied Minds president and chief executive Jill Smith said: "We are pleased to have secured participation by Riot and Bose in the funding for this high potential company, consistent with our desire to attract investment and validation from strategic and financial partners earlier in the investment life cycle where we see benefits from doing so, as we have done recently with our HawkEye 360 and BridgeSat series A rounds."

StockMarketWire.com
Allied Minds invested $22.4 million into its portfolio companies in the six months ended 30 June.

Net cash and investments at 30 June totalled $177.0m (FY16: $226.1m), of which $113.3m was held at parent level.

Other financial highlights:
- Revenue: $2.0 million (HY16: $1.3m)

- Loss for the period: $58.2 million (HY16: $52.2m), of which $44.6 million attributable to Allied Minds (HY16: $41.2m)

- The directors estimate that as of 30 June the group subsidiary ownership adjusted value was $415.8 million ($416.2m as last reported)

On 5 April Allied Minds announced a restructuring, ceasing operations at 7 subsidiaries: Biotectix; Cephalogics; CryoXtract; ProGDerm (dba Novare Pharmaceuticals); Optio Labs; RF Biocidics; and Soundcure / Tinnitus Treatment Solutions.

The group said the the plan had been substantially completed with two of the companies (Biotectix and RF Biocidics) in final stages of the process. 4

President and chief executive Jill Smith said: "We have set out clear goals for the Group with the aim of sharpening capital allocation discipline, including: transitioning to thematic investing; securing earlier and broader syndication of investment partnerships for our portfolio companies where we see scope to validate and accelerate the path to commercialisation; and strengthening the governance and leadership of our portfolio companies.

"Actions undertaken since April across our investment, syndication and operating activities have been consistent with these objectives.

"We have also set out clear goals (MBOs) for our top six companies and ABLS, based on material and commercially relevant milestones, designed to bring about tangible progress towards commercialisation.

"In the short period of time since April, these subsidiaries have progressed well against their respective MBOs, with further achievements expected for the balance of the year.

"I look forward to building on these initial steps with the team as we continue to focus on our objective to drive shareholder value by realising liquidity events that deliver attractive returns for our investors and stakeholders, and accelerating the growth of our underlying business platform."

Numis today upgrades its investment rating on Allied Minds PLC (LON:ALM) to buy (from hold) and raised its price target to 170p (from 165p).

StockMarketWire.com
Allied Minds subsidiary Spin Transfer Technologies and Tokyo Electron have signed an agreement for a collaborative engineering programme for next-generation SRAM and DRAM-class ST-MRAM devices.

Allied Minds said the combination of STT's ST-MRAM technology and TEL's advanced PVD MRAM deposition tool would allow the companies to quickly develop processes for the highest density and endurance devices.

StockMarketWire.com
SciFluor Life Sciences, a subsidiary of Allied Minds, has announced positive top-line results of a phase 1/2 trial studying the treatment of 'wet' age-related macular degeneration patients with SF0166, the company's lead eye drop drug for back of the eye diseases.

The double masked phase 1/2 study assessed the safety, tolerability and preliminary efficacy of SF0166 in 42 evaluable subjects with neovascular (wet) AMD who were randomised 1:1 to self-administer an eye drop containing either a 2.5% or a 5% solution of SF0166 twice-a-day for 28 days.

It said the primary outcome measure of safety was clearly achieved with no drug-related serious adverse events observed in the study throughout the 28-day course of treatment as well as during the 28-day follow-up period.

Ocular adverse events were recorded in the treated eyes of 5 patients; all events were mild or moderate in severity, with one considered possibly drug-related.

Credit Suisse today reaffirms its neutral investment rating on Allied Minds PLC (LON:ALM) and cut its price target to 110p (from 175p).

2 years ago these were 450p a share now 50p.

bargain.